+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of TSND-201 in adults diagnosed with Post Traumatic Stress Disorder PTSD. This Phase 3 trial is designed to test how well TSND-201 works compared to a placebo in treating PTSD symptoms. Eligible participants must have a current diagnosis of PTSD lasting at least six months and have tried previous treatments such as medication or trauma-focused psychotherapy. Participants will be randomly assigned to one of three groups two different doses of TSND-201 or a placebo. Each participant will take capsules orally once a week for four consecutive weeks during the Treatment Period. After completing treatment, participants will enter an 8-week Follow-up Period to monitor their progress without additional treatment. Throughout the study, participants will be assessed using the Clinician-Administered PTSD Scale for DSM-5 CAPS-5 to measure changes in PTSD symptom severity from baseline up to 12 weeks. Regular interviews and questionnaires will be completed to track safety and efficacy. The study aims to complete by December 2027, with careful monitoring to ensure participant well-being throughout the trial.

Age: 18Years +All GendersPhase 3
37 locations
R

Actively Recruiting

Researchers are evaluating the efficacy of ALTO-300 compared to placebo as an add-on treatment to antidepressants in adults with moderate to severe major depressive disorder MDD. This Phase 2 study aims to understand how patient characteristics might influence the effectiveness of ALTO-300 in improving depression symptoms. The study uses a randomized, double-blind, placebo-controlled design with a subsequent open-label extension phase. Participants will be assigned to receive either ALTO-300 capsules or matching placebo capsules once daily in the evening for 42 days during the double-blind period. Those who qualify for the open-label phase will continue taking ALTO-300 daily for up to an additional 8 weeks. Throughout both phases, the study monitors treatment effects and safety. During the trial, participants will undergo assessments to measure changes in depression symptoms using the Montgomery-sberg Depression Rating Scale MADRS over six weeks. Safety evaluations include monitoring adverse events, heart rate, weight, blood pressure, and suicidality through specialized questionnaires. The total study duration includes the double-blind phase and the open-label extension, with ongoing safety and efficacy monitoring until study completion.

Age: 18Years - 70YearsAll GendersPhase 2
75 locations